Breaking News, Collaborations & Alliances

Idera Pharma, NCI in Cancer Research Alliance

To evaluate TLR Antagonists for the treatment of certain lymphomas

Idera Pharmaceuticals, Inc. has entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate its toll-like receptor antagonists as a potential treatment of certain genetically defined B-cell lymphomas.
 
“We are pleased to have entered into this agreement, and we look forward to communicating further on it as the work underway proceeds,” said Sudhir Agrawal, D. Phil., chief executive officer of Idera Pharmaceuticals.  Terms of the M-CRADA were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters